ArticleClinical and experimental medicine2024

SRRM2 may be a potential biomarker and immunotherapy target for multiple myeloma: a real-world study based on flow cytometry detection.

Jinjing Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.